2017-03-07,Capricor Therapeutics To Hold Fourth Quarter And Full Year 2016 Financial Results And Corporate Update Conference Call On Wednesday, March 15
2017-02-23,Capricor Therapeutics To Present At Two Investor Conferences In March
2017-02-16,Capricor Therapeutics Provides Update On Natriuretic Peptide Program
2017-02-07,Capricor Therapeutics To Present At The 2017 BIO CEO And Investor Conference
2016-11-21,Capricor Therapeutics To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-10,Capricor Therapeutics Announces Plans To Expand Clinical Development Program In Duchenne Muscular Dystrophy To Evaluate Peripheral And Respiratory Muscle Function
2016-11-03,Capricor Therapeutics To Hold Third Quarter 2016 Business Update And Financial Results Conference Call And Webcast On Thursday, November 10 At 5:00 P.m. ET
2016-10-20,Capricor Therapeutics Awarded Up To $4.2 Million From National Institutes Of Health To Evaluate Exosomes For Hypoplastic Left Heart Syndrome
2016-10-05,Capricor Therapeutics Completes Enrollment In Phase II ALLSTAR Clinical Trial
2016-09-29,Capricor Therapeutics To Present At Upcoming Investor Conferences
2016-09-26,Capricor Therapeutics Awarded $2.4 Million From U.S. Department Of Defense To Support Manufacturing Process Development For Therapeutic Exosomes
2016-09-21,Capricor Therapeutics Announces Closing Of Public Offerings Raising Approximately $10.0 Million In Net Proceeds
2016-09-16,Capricor Therapeutics Announces Pricing Of Offerings Of Common Stock
2016-09-15,Capricor Therapeutics Announces Proposed Public Offering Of Common Stock
2016-09-07,Capricor Therapeutics Completes Enrollment in Randomized HOPE Clinical Trial in Duchenne Muscular Dystrophy
2016-09-01,Capricor Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2016-08-12,Capricor Therapeutics To Hold Second Quarter 2016 Business Update And Financial Results Conference Call And Webcast On Monday, August 15 At 4:30 P.m. ET
2016-06-23,Capricor Therapeutics Provides Enrollment Update On HOPE Clinical Trial In Duchenne Muscular Dystrophy
2016-06-22,Capricor Therapeutics To Present At JMP Life Sciences Conference
2016-05-31,Capricor Therapeutics To Present At 2016 BIO International Convention
2016-05-05,Capricor Therapeutics To Hold First Quarter 2016 Business Update And Financial Results Conference Call On May 12, 2016 At 4:30 P.m. EDT
2016-05-05,Capricor Therapeutics To Hold First Quarter 2016 Business Update And Financial Results Conference Call On May 12, 2016 At 4:30 P.m. EDT
2016-04-04,Capricor Therapeutics Announces DSMB Recommends Continuation Of HOPE-Duchenne Clinical Trial
2016-03-17,Capricor Awarded $3.4 Million Grant From California Institute For Regenerative Medicine
2016-03-15,Capricor Therapeutics Announces $4 Million Registered Direct Offering
2016-03-10,Capricor Therapeutics To Hold Fourth Quarter 2015 Financial Results And Business Update Conference Call On March 17, 2016 At 4:30 P.m. EDT
2016-03-08,Capricor Therapeutics To Present At Upcoming Investor Conferences
2016-02-23,Capricor Therapeutics Appoints Leland J. Gershell, M.D., Ph.D. As Chief Financial Officer
2016-02-22,Capricor Therapeutics Announces The First Patient With Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated With CAP-1002 In The HOPE-Duchenne Phase I/II Clinical Trial
2016-02-02,Capricor Therapeutics To Present At 18th Annual BIO CEO & Investor Conference
2016-01-05,Capricor Therapeutics To Present At Biotech Showcase 2016
2015-12-10,Capricor Therapeutics To Present At The 2015 JMP Securities DMD Forum
2015-11-24,Capricor Therapeutics To Present At The 2015 Piper Jaffray Healthcare Conference
2015-11-23,BioLife Solutions Customer Capricor Therapeutics Provides Update On Heart Failure Cell Therapy Safety Data At American Heart Association Scientific Sessions
2015-11-06,Capricor Therapeutics To Present Data From The DYNAMIC Clinical Trial At American Heart Association Scientific Sessions 2015
2015-11-04,Capricor Therapeutics To Hold Third Quarter 2015 Business Update And Financial Results Conference Call On November 12, 2015 At 4:30 P.m. EST
2015-10-29,Capricor Therapeutics And CureDuchenne To Host Webinar On November 3, 2015 At 3:00 P.m. ET
2015-09-30,Capricor Therapeutics To Present At 2015 Stem Cell Meeting On The Mesa
2015-08-13,Capricor Therapeutics Reports Second Quarter 2015 Business & Financial Highlights
2015-08-06,Capricor Therapeutics To Hold Second Quarter 2015 Business Update And Financial Results Conference Call On August 13, 2015 At 4:30 P.m. EDT
2015-08-04,Capricor Therapeutics Appoints Deborah Ascheim, M.D. As Chief Medical Officer
2015-07-30,Four Stem-Cell Stocks With Promise
2015-07-30,Pluristem, Capricor Lead Regenerative Space Says Raymond James Analyst
2015-06-17,Capricor Therapeutics Appoints Houman Hemmati M.D., Ph.D. To Vice President Of Medical And Clinical Development For New Therapies
2015-06-15,Capricor Therapeutics And CureDuchenne To Host Webinar On June 19, 2015 At 3:00 P.m. ET
2015-06-08,Capricor Announces Receipt Of FDA Clearance For The Phase I/II Study Of CAP-1002 For The Treatment Of Duchenne Muscular Dystrophy Related Cardiomyopathy
2015-05-26,Capricor Therapeutics To Participate In Two Upcoming Investor Conferences In June
2015-05-22,Ratings Changes Today
2015-05-12,Capricor Therapeutics Reports First Quarter 2015 Financial & Business Highlights
2015-05-05,Capricor Therapeutics To Hold First Quarter 2015 Business Update And Financial Results Conference Call On May 12, 2015 At 4:30 P.m. EDT
2015-04-22,Capricor Granted FDA Orphan Drug Designation For Allogeneic Cardiosphere-Derived Cells For The Treatment Of Duchenne Muscular Dystrophy
2015-04-08,Capricor Completes Enrollment Of Initial Phase Of DYNAMIC Clinical Trial Of Cardiosphere-Derived Cell Therapy For Treatment Of Advanced Heart Failure
2015-03-31,Capricor Therapeutics Completes Enrollment Of Phase II Clinical Trial For Cenderitide To Treat Heart Failure
2015-03-23,Capricor Therapeutics To Present At 3rd Annual Regen Med Investor Day On March 25, 2015 In New York
2015-03-18,Capricor Therapeutics Reports Fourth Quarter And Full Year 2014 Financial & Business Highlights
2015-03-12,Capricor Therapeutics To Hold Fourth Quarter 2014 Business Update Conference Call On March 18, 2015 At 4:30 P.m. EDT
2015-03-10,Capricor Therapeutics To Present At The 27th Annual ROTH Conference
2015-03-05,Capricor Announces Enrollment Of Its Phase II Clinical Trial For Cenderitide To Treat Heart Failure
2015-03-05,Capricor Therapeutics Announces Uplisting To NASDAQ Capital Market
2015-02-27,Capricor Therapeutics Appoints Thomas Copmann, Ph.D. As Vice President Of Regulatory Affairs And Drug Development
2015-02-04,Capricor Therapeutics Announces $7 Million Private Placement Of Common Stock
2015-01-21,Capricor Therapeutics And CureDuchenne To Host Webinar On January 21, 2015 At 3:00 P.m. ET
2015-01-12,Capricor Therapeutics Initiates The DYNAMIC Clinical Trial For The Treatment Of Advanced Heart Failure
2015-01-12,Capricor Therapeutics Announces $10 Million Private Placement Of Common Stock
2014-12-02,Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present A Company Overview And Serve As An Expert Panelist At Piper Jaffray's 26th Annual Healthcare Conference
2014-11-18,Capricor Therapeutics Announces Favorable ALLSTAR Phase I Safety Results
2014-11-18,Capricor Therapeutics Announces Positive Pre-Clinical Data For Cardiosphere-Derived Cells (CDCs) On Duchenne Muscular Dystrophy Cardiomyopathy
2014-11-12,Capricor Therapeutics Reports Third Quarter 2014 Financial & Business Highlights
2014-11-07,Capricor Therapeutics To Hold Duchenne Muscular Dystrophy Data Presentation Call On November 18, 2014 At 9:30 A.m. ET
2014-10-31,Capricor Therapeutics To Hold Third Quarter 2014 Business Update Conference Call On November 12, 2014 At 4:30 P.m. ET
2014-10-14,Capricor Therapeutics Announces Acquisition Of Intellectual Property Rights To Family Of Natriuretic Peptides From Medtronic, Inc.
2014-10-09,Capricor Therapeutics Announces Plans To Pursue A Cenderitide Clinical Program And Enters Into Research Support Agreement With Insulet Corporation
2014-10-06,Capricor Announces Plans To Pursue Clinical Program For The Treatment Of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs)
2014-09-18,Capricor Presents Safety And Preliminary Efficacy Results From ALLSTAR Phase I Clinical Trial At TCT 2014
2014-08-13,Capricor Therapeutics Reports Second Quarter 2014 Financial & Business Highlights
2014-08-04,Capricor Therapeutics To Hold Second Quarter 2014 Business Update Conference Call On August 13, 2014 At 4:30 P.m. Eastern Time
2014-07-16,Capricor Announces Encouraging Results From Phase I ALLSTAR Trial; Phase II Trial Underway
2002-04-01,Three to Eye: Hasbro, Gateway, Isle of Capri
,
,
,
2017-03-07,Capricor Therapeutics To Hold Fourth Quarter And Full Year 2016 Financial Results And Corporate Update Conference Call On Wednesday, March 15
2017-02-23,Capricor Therapeutics To Present At Two Investor Conferences In March
2017-02-16,Capricor Therapeutics Provides Update On Natriuretic Peptide Program
2017-02-07,Capricor Therapeutics To Present At The 2017 BIO CEO And Investor Conference
2016-11-21,Capricor Therapeutics To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-10,Capricor Therapeutics Announces Plans To Expand Clinical Development Program In Duchenne Muscular Dystrophy To Evaluate Peripheral And Respiratory Muscle Function
2016-11-03,Capricor Therapeutics To Hold Third Quarter 2016 Business Update And Financial Results Conference Call And Webcast On Thursday, November 10 At 5:00 P.m. ET
2016-10-20,Capricor Therapeutics Awarded Up To $4.2 Million From National Institutes Of Health To Evaluate Exosomes For Hypoplastic Left Heart Syndrome
2016-10-05,Capricor Therapeutics Completes Enrollment In Phase II ALLSTAR Clinical Trial
2016-09-29,Capricor Therapeutics To Present At Upcoming Investor Conferences
2016-09-26,Capricor Therapeutics Awarded $2.4 Million From U.S. Department Of Defense To Support Manufacturing Process Development For Therapeutic Exosomes
2016-09-21,Capricor Therapeutics Announces Closing Of Public Offerings Raising Approximately $10.0 Million In Net Proceeds
2016-09-16,Capricor Therapeutics Announces Pricing Of Offerings Of Common Stock
2016-09-15,Capricor Therapeutics Announces Proposed Public Offering Of Common Stock
2016-09-07,Capricor Therapeutics Completes Enrollment in Randomized HOPE Clinical Trial in Duchenne Muscular Dystrophy
2016-09-01,Capricor Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2016-08-12,Capricor Therapeutics To Hold Second Quarter 2016 Business Update And Financial Results Conference Call And Webcast On Monday, August 15 At 4:30 P.m. ET
2016-06-23,Capricor Therapeutics Provides Enrollment Update On HOPE Clinical Trial In Duchenne Muscular Dystrophy
2016-06-22,Capricor Therapeutics To Present At JMP Life Sciences Conference
2016-05-31,Capricor Therapeutics To Present At 2016 BIO International Convention
2016-05-05,Capricor Therapeutics To Hold First Quarter 2016 Business Update And Financial Results Conference Call On May 12, 2016 At 4:30 P.m. EDT
2016-05-05,Capricor Therapeutics To Hold First Quarter 2016 Business Update And Financial Results Conference Call On May 12, 2016 At 4:30 P.m. EDT
2016-04-04,Capricor Therapeutics Announces DSMB Recommends Continuation Of HOPE-Duchenne Clinical Trial
2016-03-17,Capricor Awarded $3.4 Million Grant From California Institute For Regenerative Medicine
2016-03-15,Capricor Therapeutics Announces $4 Million Registered Direct Offering
2016-03-10,Capricor Therapeutics To Hold Fourth Quarter 2015 Financial Results And Business Update Conference Call On March 17, 2016 At 4:30 P.m. EDT
2016-03-08,Capricor Therapeutics To Present At Upcoming Investor Conferences
2016-02-23,Capricor Therapeutics Appoints Leland J. Gershell, M.D., Ph.D. As Chief Financial Officer
2016-02-22,Capricor Therapeutics Announces The First Patient With Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated With CAP-1002 In The HOPE-Duchenne Phase I/II Clinical Trial
2016-02-02,Capricor Therapeutics To Present At 18th Annual BIO CEO & Investor Conference
2016-01-05,Capricor Therapeutics To Present At Biotech Showcase 2016
2015-12-10,Capricor Therapeutics To Present At The 2015 JMP Securities DMD Forum
2015-11-24,Capricor Therapeutics To Present At The 2015 Piper Jaffray Healthcare Conference
2015-11-23,BioLife Solutions Customer Capricor Therapeutics Provides Update On Heart Failure Cell Therapy Safety Data At American Heart Association Scientific Sessions
2015-11-06,Capricor Therapeutics To Present Data From The DYNAMIC Clinical Trial At American Heart Association Scientific Sessions 2015
2015-11-04,Capricor Therapeutics To Hold Third Quarter 2015 Business Update And Financial Results Conference Call On November 12, 2015 At 4:30 P.m. EST
2015-10-29,Capricor Therapeutics And CureDuchenne To Host Webinar On November 3, 2015 At 3:00 P.m. ET
2015-09-30,Capricor Therapeutics To Present At 2015 Stem Cell Meeting On The Mesa
2015-08-13,Capricor Therapeutics Reports Second Quarter 2015 Business & Financial Highlights
2015-08-06,Capricor Therapeutics To Hold Second Quarter 2015 Business Update And Financial Results Conference Call On August 13, 2015 At 4:30 P.m. EDT
2015-08-04,Capricor Therapeutics Appoints Deborah Ascheim, M.D. As Chief Medical Officer
2015-07-30,Four Stem-Cell Stocks With Promise
2015-07-30,Pluristem, Capricor Lead Regenerative Space Says Raymond James Analyst
2015-06-17,Capricor Therapeutics Appoints Houman Hemmati M.D., Ph.D. To Vice President Of Medical And Clinical Development For New Therapies
2015-06-15,Capricor Therapeutics And CureDuchenne To Host Webinar On June 19, 2015 At 3:00 P.m. ET
2015-06-08,Capricor Announces Receipt Of FDA Clearance For The Phase I/II Study Of CAP-1002 For The Treatment Of Duchenne Muscular Dystrophy Related Cardiomyopathy
2015-05-26,Capricor Therapeutics To Participate In Two Upcoming Investor Conferences In June
2015-05-22,Ratings Changes Today
2015-05-12,Capricor Therapeutics Reports First Quarter 2015 Financial & Business Highlights
2015-05-05,Capricor Therapeutics To Hold First Quarter 2015 Business Update And Financial Results Conference Call On May 12, 2015 At 4:30 P.m. EDT
2015-04-22,Capricor Granted FDA Orphan Drug Designation For Allogeneic Cardiosphere-Derived Cells For The Treatment Of Duchenne Muscular Dystrophy
2015-04-08,Capricor Completes Enrollment Of Initial Phase Of DYNAMIC Clinical Trial Of Cardiosphere-Derived Cell Therapy For Treatment Of Advanced Heart Failure
2015-03-31,Capricor Therapeutics Completes Enrollment Of Phase II Clinical Trial For Cenderitide To Treat Heart Failure
2015-03-23,Capricor Therapeutics To Present At 3rd Annual Regen Med Investor Day On March 25, 2015 In New York
2015-03-18,Capricor Therapeutics Reports Fourth Quarter And Full Year 2014 Financial & Business Highlights
2015-03-12,Capricor Therapeutics To Hold Fourth Quarter 2014 Business Update Conference Call On March 18, 2015 At 4:30 P.m. EDT
2015-03-10,Capricor Therapeutics To Present At The 27th Annual ROTH Conference
2015-03-05,Capricor Announces Enrollment Of Its Phase II Clinical Trial For Cenderitide To Treat Heart Failure
2015-03-05,Capricor Therapeutics Announces Uplisting To NASDAQ Capital Market
2015-02-27,Capricor Therapeutics Appoints Thomas Copmann, Ph.D. As Vice President Of Regulatory Affairs And Drug Development
2015-02-04,Capricor Therapeutics Announces $7 Million Private Placement Of Common Stock
2015-01-21,Capricor Therapeutics And CureDuchenne To Host Webinar On January 21, 2015 At 3:00 P.m. ET
2015-01-12,Capricor Therapeutics Initiates The DYNAMIC Clinical Trial For The Treatment Of Advanced Heart Failure
2015-01-12,Capricor Therapeutics Announces $10 Million Private Placement Of Common Stock
2014-12-02,Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present A Company Overview And Serve As An Expert Panelist At Piper Jaffray's 26th Annual Healthcare Conference
2014-11-18,Capricor Therapeutics Announces Favorable ALLSTAR Phase I Safety Results
2014-11-18,Capricor Therapeutics Announces Positive Pre-Clinical Data For Cardiosphere-Derived Cells (CDCs) On Duchenne Muscular Dystrophy Cardiomyopathy
2014-11-12,Capricor Therapeutics Reports Third Quarter 2014 Financial & Business Highlights
2014-11-07,Capricor Therapeutics To Hold Duchenne Muscular Dystrophy Data Presentation Call On November 18, 2014 At 9:30 A.m. ET
2014-10-31,Capricor Therapeutics To Hold Third Quarter 2014 Business Update Conference Call On November 12, 2014 At 4:30 P.m. ET
2014-10-14,Capricor Therapeutics Announces Acquisition Of Intellectual Property Rights To Family Of Natriuretic Peptides From Medtronic, Inc.
2014-10-09,Capricor Therapeutics Announces Plans To Pursue A Cenderitide Clinical Program And Enters Into Research Support Agreement With Insulet Corporation
2014-10-06,Capricor Announces Plans To Pursue Clinical Program For The Treatment Of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs)
2014-09-18,Capricor Presents Safety And Preliminary Efficacy Results From ALLSTAR Phase I Clinical Trial At TCT 2014
2014-08-13,Capricor Therapeutics Reports Second Quarter 2014 Financial & Business Highlights
2014-08-04,Capricor Therapeutics To Hold Second Quarter 2014 Business Update Conference Call On August 13, 2014 At 4:30 P.m. Eastern Time
2014-07-16,Capricor Announces Encouraging Results From Phase I ALLSTAR Trial; Phase II Trial Underway
2002-04-01,Three to Eye: Hasbro, Gateway, Isle of Capri
,
,
,
